

Datasheet for ABIN3025027
anti-IDH1 antibody (AA 280-420)



[Go to Product page](#)

1 Image

Overview

Quantity:	100 µg
Target:	IDH1
Binding Specificity:	AA 280-420
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This IDH1 antibody is un-conjugated
Application:	Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details

Immunogen:	A recombinant fragment (119 amino acid residues around aa 280-420) from the human protein was used as the immunogen for the IDH1 antibody.
Clone:	IDH1-1152
Isotype:	IgG1 kappa
Characteristics:	It recognizes a 45 kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming α-ketoglutarate and CO ₂ in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of α-ketoglutarate. During this process, either NADH or NADPH is produced along with CO ₂ .

Product Details

Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Purification: Protein G affinity chromatography

Target Details

Target: IDH1

Alternative Name: IDH1 ([IDH1 Products](#))

Background: It recognizes a 45 kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO₂ in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO₂. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Pathways: [Warburg Effect](#)

Application Details

Application Notes: Optimal dilution of the IDH1 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0 or 10 mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 µg/million cells in 0.1ml,Immunofluorescence: 0.5-1 µg/mL,Western blot: 0.5-1 µg/mL,Immunohistochemistry (FFPE): 0.5-1 µg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2)

Restrictions: For Research Use only


Handling

Concentration: 1 mg/mL

Handling

Buffer:	1 mg/mL in 1X PBS, BSA free, sodium azide free
Preservative:	Azide free
Storage:	4 °C,-20 °C
Storage Comment:	Store the IDH1 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Images



Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections)

Image 1. Formalin-fixed, paraffin-embedded human colon carcinoma stained with IDH1 antibody (IDH1/1152).